Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

  Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent
                          Ibrutinib Royalty Purchase

Royalty Pharma's Third Phase III Investment in the Last 18 Months

PR Newswire

NEW YORK, Aug. 12, 2013

NEW YORK, Aug. 12, 2013 /PRNewswire/ --RoyaltyPharmaannounced today that,
pursuant to a collaboration with AislingCapitaland ClarusVentures, it has
sold to Aisling and Clarusapproximately 20% of the royalty interest in
ibrutinib it recently acquired from Quest Diagnostics (NYSE: DGX) for a pro
rata percentage of the $485 million Royalty Pharma paid to Quest for the

(Logo: )

"The Clarus and Aisling teams' expertise in early-stage and development-stage
companies and therapies added real value during the course of our collective
consideration of this opportunity. We greatly enjoyed working with Aisling
and Clarusand look forward tofuturepotential joint opportunities in which
we can pool our resources and expertise," said Pablo Legorreta, Founder and
Chief Executive Officer of Royalty Pharma. "The ibrutinib transaction marks
Royalty Pharma'sthird pre-FDAapproval investment in 18 months. We see many
other quality pre-approval products where RoyaltyPharmacouldprovide
liquidity to drug developers by pulling forward future revenues. Such
high-quality pre-approval investment opportunities are an excellent complement
to Royalty Pharma's core business of acquiring royalty assets on approved
drugs,"added Mr. Legorreta.

"This collaboration brought together the capabilities of each firm in an
extremely effective manner," noted Dennis Purcell, Senior Managing Director at
Aisling Capital.

"Ibrutinib is an important advance in the treatment of multiple B-cell
malignancies," added Nick Simon, Managing Director at Clarus Ventures. "We
are excited to be part of the story."

Pharmacyclics (NASDAQ: PCYC) and Janssen Pharmaceutical's(NYSE: JNJ)
ibrutinibwas filed with the U.S. Food and Drug Administration (FDA) in July
2013 for relapsed/refractory mantle cell lymphoma and relapsed/refractory
chronic lymphocytic leukemia after receiving Breakthrough Therapy Designation
from FDA earlier this year.Ibrutinibhas received three of the eight
Breakthrough Therapy Designations granted by the FDA to date in oncology.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in
marketed and late stage biopharmaceutical products. With over $10 billion in
assets, Royalty Pharma owns royalty interests in 41 marketed and late stage
biopharmaceutical products, including Abbott's Humira®, Johnson and Johnson's
Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®,
Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®,
Astella's Lexiscan®, Merck's Januvia/Janumet®, Roche's Mircera®, UCB's
Cimzia®, Biogen Idec's Tecfidera® and Pharmacyclics' ibrutinib. Additional
company information is available at

About Clarus Ventures

Clarus Ventures is a life sciences venture capital firm founded by a team of
accomplished investment and operating professionals. The investment team has
extensive and broad backgrounds in research and development,
commercialization, business development and operations management, which
enabled Clarus to establish a long history of success in creating value across
multiple disciplines within the healthcare-investing universe. The deep domain
expertise of the Clarus team allows us to employ a hands-on philosophy of
providing value enhanced leadership and guidance in working with our
management teams in both the biopharmaceutical and medical device arenas.
Clarus is presently managing $1.2 billion. The firm invests globally out of
its offices in Cambridge, MA and South San Francisco, CA.

About Aisling Capital

Aisling Capital is a life sciences-dedicated venture capital firm with over
US$1.6 billion under management. The firm invests in companies developing
pharmaceutical and medical products, as well as in businesses that provide
drug development, manufacturing and other important services to the healthcare
industry. Headquartered in New York, Aisling invests in both private and
public companies utilizing a wide variety of investment structures. The
Aisling Capital team's combination of clinical, operational, transactional and
capital markets experience allows the firm to identify, execute and realize
investments across the life sciences industry.

For Royalty Pharma:
Alexander v. Perfall (investors and media) at 212-883-2298
George Lloyd (royalty holders) at 212-883-2275

SOURCE Royalty Pharma

Press spacebar to pause and continue. Press esc to stop.